FIGURE LEGENDS
Figure 1. Plasma
concentration-time profile of mycophenolic acid.
Figure 2. Comparison of Ka and its variability between
base model (A) and covariate model (B). The random variable η is
normally distributed with mean zero and variance of ω², which is the
deviation of ηi from population value.
Figure 3. The variation of clearance rate before (A, B) and after
addition of covariate (C, D). The random variable η is normally
distributed with mean zero and variance of ω², which is the deviation of
ηi from population value.
Figure 4. Covariate effects on pharmacokinetic parameters of
mycophenolic acid. The X-axis is inter-individual variation (η)
expressed by the mean±SD.
Figure 5. Distribution of estimated glomerular filtration rate (eGFR)
calculated with the measurement of serum creatinine and cystatin C.
Figure 6. Goodness-of-fit plots of mycophenolic acid for population
pharmacokinetic model. Observed concentration versus population (A) and
individual (B) predictions, and conditional weighted residuals versus
population predictions (C) and time from dose (D). y =±2 represents 95%
confidence interval.
Figure 7. Visual predictive check for mycophenolic acid. The blank dots
are actual observations. The redlines are 5th (solid
line), 50th and 95th (dash lines)
quantiles from actual observations within their simulated 95% CIs
(shaded areas).
SUPPORTING INFORMATION
Supplemental Figure1.The effect of prednisolone on absorption (P=0.017).
Supplemental Table 1. Dosage simulations of mycophenolate mofetil for
ANCA-associated nephritis children (N=1000) based on different estimated
glomerular filtration rates (eGFR) and myeloperoxidase